Lexaria Bioscience (LEXX) investor relations material

Company overview and business model

• DehydraTECH combines active pharmaceutical ingredients with fatty-acid-rich oils and carrier compounds to target improved absorption, effectiveness, tolerability and oral delivery at lower doses.

• Potential applications span GLP-1/GIP drugs, glucagon, vitamins, pain medicines, hormones, antivirals, nicotine and cannabinoids; therapeutic areas include diabetes, weight loss, epilepsy, hypertension and heart disease.

• Delivery formats include suspensions, tablets, capsules, foods, beverages and oral pouches for pharmaceutical, nutraceutical, OTC and consumer products.

Financial performance and metrics

• September 2026 warrant inducement generated ~$5.9M gross cash proceeds from exercise of 453,969 existing warrants at a reduced $12.92/share price, before fees and expenses.

• As of Oct. 1, 2026, 2,106,528 common shares were outstanding; pro forma shares would be 3,030,355 if all registered warrants were exercised.

• The auditor’s report on FY ended Aug. 31, 2025 financial statements includes an explanatory paragraph regarding ability to continue as a going concern.

Use of proceeds and capital allocation

• No proceeds from selling-stockholder resales; cash exercise of all registered warrants could yield ~$11.76M, but exercise timing and occurrence are uncertain.

• Potential warrant proceeds are intended for future R&D, working capital and general corporate purposes.

• Net proceeds from the September 2026 inducement are intended for working capital and general corporate purposes.